Low tissue levels of the major marine ω3 fatty acids (FAs) DHA and EPA are found in Alzheimer’s disease (AD). We investigated if healthy proxies to AD patients have higher levels of these ω3 FAs. We observed lower levels of EPA and DHA in subcutaneous adipose tissue biopsies from 64 AD patients compared with 16 cognitively healthy proxies. No significant difference was observed when pairwise comparisons were made between a subset of 16 AD patients and their co-habiting proxies. Larger studies are needed to replicate these findings and to determine if they could depend on FA intake or differences in metabolism.
CederholmT, SalemN, PalmbladJ (2013) ω-3 fatty acids inthe prevention of cognitive decline in humans. Adv Nutr4, 672–676.
2.
DangourAD, AndreevaVA, SydenhamE Uauy R (2012) Omega 3 fattyacids and cognitive health in older people. Br J Nutr107, S152–S158.
3.
SchaeferEJ, BongardV, BeiserAS, Lamon-FavaS, RobinsSJ, AuR, TuckerKL, KyleDJ, WilsonPW, WolfPA (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: The Framingham Heart Study. Arch Neurol63, 1545–1550.
4.
LinPY, ChiuCC, HuangSY, SuKP (2012) A meta-analytic review of polyunsaturated fatty acid composition in dementia. J Clin Psychiatry73, 1245–1254.
5.
SoderbergM, EdlundC, KristenssonK, DallnerG (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease. Lipids26, 421–425.
MartinV, FabeloN, SantpereG, PuigB, MarinR, FerrerI, DiazM (2010) Lipid alterations in lipid rafts from Alzheimer’s disease human brain cortex. J Alzheimers Dis19, 489–502.
8.
HodsonL, Murray SkeaffC, FieldingBA (2008) Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res47, 348–380.
9.
KatanMB, DeslypereJP, van BirgelenAP, PendersM, ZegwaardM (1997) Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: An 18-month controlled study. J Lipid Res38, 2012–2022.
CarlisleA, GibsonEL, DyallSC (2016) A high omega-3 fatty acid multinutrient supplement benefits cognition and mobility in older women: A randomized, double-blind, placebo-controlled pilot study. J Gerontol A Biol Sci Med Sci71, 236–242.
12.
LeeLK, ShaharS, ChinAV, YusoffNA (2013) Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): A 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology225, 605–612.
13.
Freund LeviY, VedinI, CederholmT, BasunH, Faxén IrvingG, EriksdotterM, HjorthE, SchultzbergM, VessbyB, WahlundLO, SalemNJr, PalmbladJ (2014) Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer’s disease – the OmegAD study. J Intern Med275, 428–436.
14.
Freund LeviY, CederholmT, Eriksdotter-JönhagenM, BasunH, Faxén IrvingG, GarlindA, Tysén-BackströmA, VedinI, VessbyB, WahlundL-O, PalmbladJ (2006) Omega-3 fatty acid supplementation delays the cognitive decline in patients with very mild Alzheimer’s disease – a 1-year randomised placebo-controlled study of 174 patients. Arch Neurol63, 1402–1408.
15.
BobergM, CroonLB, GustafssonIB, VessbyB (1985) Platelet fatty acid composition in relation to fatty acid composition in plasma and to serum lipoprotein lipids in healthy subjects with special reference to the linoleic acid pathway. Clin Sci (Lond)68, 581–587.
16.
Lopes da SilvaS, VellasB, ElemansS, LuchsingerJ, KamphuisP, YaffeK, SijbenJ, GroenendijkM, StijnenT (2014) Plasma nutrient status of patients with Alzheimer’s disease: Systematic review and meta-analysis. Alzheimers Dement10, 485–502.
17.
RapoportSI (2013) Translational studies on regulation of brain docosahexaenoic acid (DHA) metabolism in vivo. Prostaglandins Leukot Essent Fatty Acids88, 79–85.
18.
AstaritaG, JungKM, BerchtoldNC, NguyenVQ, GillenDL, HeadE, CotmanCW, PiomelliD (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer’s disease. PLoS One5, e12538.
19.
Bourdel-MarchassonI, Delmas-BeauvieuxMC, PeuchantE, DecampsA, ReignierB, EmeriauJP, RainfrayM (2001) Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Aging30, 235–241.
